LifeSciences BC > News > Member Announcements

DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

September 11, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Sept. 11, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that CEO Saiid Zarrabian will deliver a presentation on the Company and meet with investors at the Fall Investor Summit on September 16, 2019 at 1:30 PM ET in … Continue reading DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

September 10, 2019
DelMar Pharmaceuticals Inc.

Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020 SAN DIEGO, Sept. 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results … Continue reading DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

September 9, 2019
XENON PHARMACEUTICALS INC.

Flexion’s new locally delivered product candidate, FX301, will combine Xenon’s NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel FX301 is a potential first-in-class therapy with the aim of providing pain relief via peripheral nerve block for up to a week following surgery while preserving motor function Acquisition of XEN402 expands Flexion’s portfolio focused on developing … Continue reading Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

ABCELLERA APPOINTS ANDREW BOOTH AS CHIEF FINANCIAL OFFICER AND TRYN STIMART AS GENERAL COUNSEL

September 9, 2019

Today AbCellera announced the expansion of its executive team with the hiring of Andrew Booth as Chief Financial Officer and Tryn Stimart as General Counsel.  In his role as CFO, Andrew Booth will assume responsibility for corporate finance and growth, and as General Counsel, Tryn Stimart will oversee all corporate legal matters and lead AbCellera’s … Continue reading ABCELLERA APPOINTS ANDREW BOOTH AS CHIEF FINANCIAL OFFICER AND TRYN STIMART AS GENERAL COUNSEL

DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

September 9, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Sept. 9, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that on September 6, 2019, the Company was formally notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained full compliance with all criteria for continued … Continue reading DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 5, 2019
Neoleukin Therapeutics, Inc.

SEATTLE, Sept. 05, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it has granted equity awards that were approved by the Compensation Committee of its Board of Directors on August 31, 2019 as a material inducement to employment to four individuals hired by Neoleukin. The equity awards were … Continue reading Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

September 4, 2019
DelMar Pharmaceuticals Inc.

SAN DIEGO, Sept. 4, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company has relocated its headquarters from Vancouver, British Columbia to San Diego, California. “Our move to the San Diego area is an important step in the … Continue reading DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases

August 28, 2019
Chinook Therapeutics Inc.

VANCOUVER, British Columbia, Aug. 22, 2019 /PRNewswire/ — Chinook Therapeutics, Inc. today announced a $65 million Series A financing to discover and develop precision medicines for kidney diseases. Founding investor Versant Ventures led the round with participation by fellow founding investor Apple Tree Partners and new investor Samsara BioCapital. The Series A proceeds will fund … Continue reading Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases

DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

August 27, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that its current cash position, which includes the $6.7 million in net proceeds from the underwritten offering completed August … Continue reading DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors

August 20, 2019
Arbutus Biopharma Corp.

WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019. “We are pleased to welcome Dr. Cheng to the Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board … Continue reading Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors